Association of midlife antibiotic use with subsequent cognitive function in women

Raaj S. Mehta¹, Paul Lochhead¹, Yiqing Wang¹, Wenjie Ma¹, Long H. Nguyen¹, Bharati Kochar¹, Curtis Huttenhower², Francine Grodstein³‡, Andrew T. Chan¹,4‡*

¹ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, ² Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, ³ Rush Alzheimer’s Disease Center, Rush University Medical Center and Department of Internal Medicine, Rush Medical College, Chicago, Illinois, United States of America, ⁴ Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

‡ These authors are Co-senior authors on this work.
* achan@mgh.harvard.edu

Abstract

The gut microbiome is increasingly recognized to play a role in cognition and dementia. Antibiotic use impacts the gut microbiome and has been linked with chronic disease. Despite these data, there is no evidence supporting an association between long-term antibiotic use in adults and cognitive function. We conducted a prospective population-based cohort study among 14,542 participants in the Nurses’ Health Study II who completed a self-administered computerized neuropsychological test battery between 2014–2018. Multivariate linear regression models were used to assess if chronic antibiotic use in midlife was associated with cognitive impairment assessed later in life. Women who reported at least 2 months of antibiotic exposure in midlife (mean age 54.7, SD 4.6) had lower mean cognitive scores seven years later, after adjustment for age and educational attainment of the spouse and parent, with a mean difference of -0.11 standard units for the global composite score (P_trend < 0.0001), -0.13 for a composite score of psychomotor speed and attention (P_trend < 0.0001), and -0.10 for a composite score of learning and working memory (P_trend < 0.0001) compared with non-antibiotic users. These differences were not materially changed after multivariate adjustment for additional risk factors, including comorbid conditions. As a benchmark, the mean difference in score associated with each additional year of age was (-0.03) for global cognition, (-0.04) for psychomotor speed and attention, and (-0.03) for learning and working memory; thus the relation of antibiotic use to cognition was roughly equivalent to that found for three to four years of aging. Long-term antibiotic use in midlife is associated with small decreases in cognition assessed seven years later. These data underscore the importance of antibiotic stewardship, especially among aging populations.

Introduction

The brain-gut axis [1] as mediated by the intestinal microbiome may contribute to neuropsychiatric illnesses including depression [2], schizophrenia [3], autism [4], and anxiety [5].
Emerging evidence also suggests a role of the gut microbiome in the etiopathogenesis of dementia. Animal data indicate that alterations in oral [6] and intestinal bacteria [7,8] may be involved in formation of amyloid plaques. Small, cross-sectional studies suggest large taxonomic differences between participants with and without Alzheimer’s Disease [9].

Chronic antibiotic use has been associated with an increased risk of conditions related to chronic inflammation, including obesity [10], cancer [11], and colonic neoplasia [12]. One recent study found that antibiotic use in the fifth and sixth decades of life—​not at older or younger ages—​was associated with incident cardiovascular disease [13]. These associations may be mediated by antibiotic-induced alterations in gut microbial communities [14,15]. Despite recovery of some bacterial species after completion of antibiotic treatment, overall shifts in gut microbial taxonomic communities and changes to certain bacterial genes persist months to years after drug exposure [16–18].

Evidence linking antibiotic use with cognition is limited. Experimental studies have shown that antibiotic administration causes changes in behavior [19] and impaired spatial memory [20]. In humans, early life antibiotic exposure is associated with worse cognitive outcomes in children [21,22], and among patients with Alzheimer’s disease, twelve months of treatment with doxycycline and rifampin compared to placebo led to declines in cognition [23]. To our knowledge, there are no studies examining midlife antibiotic use with subsequent cognitive function in participants without dementia.

Therefore, we investigated the association between duration of midlife antibiotic use (within the sixth decade of life) with validated measures of cognition assessed a mean of 7.0 years (SD 0.7) years later among women enrolled in the Nurses’ Health Study II (NHS2) where information on cumulative antibiotic use during adulthood, as well as other lifestyle risk factors, has been prospectively collected.

Materials and methods

Study population

The Nurses’ Health Study II is an ongoing US-nationwide prospective cohort study, which began in 1989 with the enrollment of 116,430 female nurses aged 25–42 years [24]. Every two years, participants return questionnaires with detailed information on lifestyle, medication, and health-related factors. Follow-up on each biennial questionnaire exceeds 90%. The Human Research Committees of the Brigham and Women’s Hospital approved this study. Consent was implied by return of written questionnaires.

Assessment of midlife antibiotic use

In 2009, NHS2 participants (mean age 54.7, SD 4.6) were asked to report their total duration of antibiotic use in 7 categories (ranging from none to 3+ years) over the preceding 4 years, which was then called midlife antibiotic use. Participants were asked to report the most common reason that an antibiotic was used with the following response categories: respiratory infection, urinary tract infection (UTI), acne/roacea, chronic bronchitis, dental, and other reason.

Assessment of cognition

A mean of 7.0 years (SD 0.7) after our primary exposure was ascertained from the 2009 questionnaire, we administered CogState, a standardized and validated, self-administered, online cognitive battery in which deficits have previously been shown to be associated with dementia [25]. Between 2014 and 2018, 15,129 women completed the neuropsychological battery using a...
computer at home. The characteristics of women who accepted the CogState invitation were similar to those who did not respond [26]. The battery comprised four tasks presented in the following order: Detection, measuring psychomotor function and information processing speed, in which women press a key when a playing card on the screen flips over; Identification, measuring vigilance and visual attention, in which women press a key when a red card flips over; One Card Learning, which measures visual learning and short-term memory, in which women are shown playing cards and asked to remember if they have seen the card previously; and One Back, which measures attention and working memory, in which women are asked if the card on the screen is identical to the card shown just before [26,27]. As per prior studies [26,27], we generated three composite scores by averaging standardized scores (z-scores) from individual CogState tasks. A composite score of psychomotor speed and attention was derived from Detection and Identification, a composite measure of learning and working memory from One Card Learning and One Back, and a composite score for global cognition from the z-scores for all four tasks.

**Assessment of other potential confounding variables**

As described in prior studies [27], as a proxy for socioeconomic status, the nurse’s spouse’s highest educational level was queried in 1999 (high school, undergraduate, postgraduate, unmarried/unknown). Participants were asked about the highest educational level of either parent in 2005 (high school, undergraduate, postgraduate, unknown).

Diet quality derived from food frequency questionnaires was assessed using the Alternative Health Eating Index (AHEI) 2010 without alcohol, returned every 4 years [28]. As in prior studies [27], we used cumulative average values from 1999–2011 to minimize variance and represent long-term patterns. Regular use of antidepressants and symptoms of depression was assessed in 2013. Along with dietary data collection, alcohol consumption was assessed according to number of drinks per day (beer, wine, liquor) every 4 years, and then converted to grams of alcohol per day: “none”, “1–14 g/day”, or ≥15 g/day.

The remainder of covariates, including body mass index, smoking status, regular use of multivitamins, history of high blood pressure (yes/no), history of high cholesterol (yes/no), history of type 2 diabetes (yes/no), history of emphysema (yes/no), history of stroke (yes/no), history of myocardial infarction (yes/no) regular use of aspirin or nonsteroidal anti-inflammatory drugs (yes/no), physical activity (continuous, MET-hours/week) were assessed at the time of exposure in 2009.

**Statistical analysis**

Among the 15,129 women who completed the CogState battery, consistent with previous studies [27] we excluded participants who failed integrity checks on all 4 CogState tasks, who had insufficient data to calculate at least 1 composite cognitive score, or did not provide antibiotic data, leaving 14,542 women for analysis. For the primary analysis, we examined midlife antibiotic use (categorized as none, 1–14 days, 15 days– 2 months, and 2+ months) in relation to the following three composite scores: psychomotor speed and attention, learning and working memory, and global cognition, using linear regression models. Our base model was adjusted for age at the time of cognitive assessment and educational attainment of parents and spouse. Our multivariable models were additionally adjusted for body mass index, regular use of antidepressants or depression symptoms, smoking status, regular use of multivitamins, high blood pressure, high cholesterol, type 2 diabetes, emphysema, history of stroke, history of myocardial infarction, regular use of aspirin or nonsteroidal anti-inflammatory drugs, physical activity, and dietary scores. Relative to the referent category of those who used no antibiotics (none),
we computed β estimates (mean differences) and 95% confidence intervals (CI) for cognitive scores for each category of use duration as per prior studies [27]. To test for linear trend, we used the median of each category of duration of use as a continuous variable. In secondary analyses, we also examined the association between the reason for midlife antibiotic use with cognitive scores. To address confounding by indication and/or effect modification by age, chronic medical conditions, or other medications, we performed stratified analyses by presence of comorbidities (history of type 2 diabetes, myocardial infarction, stroke, and emphysema), age > 65, and regular use of antidepressants. Analyses were performed using SAS v 9.4 (SAS Institute, Cary, NC).

P < 0.05 was considered significant.

Results

We identified 14,542 women in the NHS2 cohort who completed cognitive testing and completed medication questionnaires. The mean age at the time of cognitive testing between 2014–2018 was 61.7 years (SD 4.6). Women who reported a longer duration of antibiotic use at midlife (mean age 54.7, SD 4.6) were generally similar to women who did not report any chronic antibiotic use in terms of alcohol intake, educational attainment of parents and spouse, and BMI; however, they were more likely to use antidepressants and aspirin and to have a history of myocardial infarction, stroke, and emphysema (Table 1).

Increasing total exposure to antibiotics in midlife was significantly associated with poorer scores for all three cognitive domains (Table 2). Compared to non-users, women who used antibiotics for at least two months had mean scores that were lower by 0.11 standard units for global cognition ($P_{\text{trend}} = 0.002$), 0.13 for psychomotor speed and attention ($P_{\text{trend}} = 0.004$), and 0.10 for learning and working memory ($P_{\text{trend}} = 0.03$), after adjustment for age and educational attainment of the parent and spouse. This association remained after multivariable adjustment for risk factors for cognitive decline, including medical comorbidities. To assist in interpretation of the CogState score data, we found the mean score differences associated with each additional year of age to be -0.03 for global cognition, -0.04 for psychomotor speed and attention, and -0.03 for learning and working memory (Table 2). Thus, the effect estimates that we found for antibiotic use were equivalent to the effect estimates we would expect for three to four years of aging.

The most common indication for chronic antibiotic use was respiratory infections, followed by "other" (including acne), urinary tract infections (UTI), and dental indications. Although sample size was limited within antibiotic use indication subgroups, the most substantial differences in cognitive scores appeared to be in the subgroup of women using antibiotics for respiratory infections or UTIs (global score difference for users vs. non-users was -0.04 and -0.04, respectively) (S1 Table).

We examined the association of chronic antibiotic use and global cognition within subgroups stratified by age, presence or absence of history of diabetes mellitus, emphysema, MI, stroke, or COPD; and regular use or non-use of antidepressants. The associations between antibiotic use with cognitive scores were generally similar between strata, and $p_{\text{int}}$ were not significant using the continuous variable for trend (Table 3).

Discussion

In a cohort of over 14,000 women, we observed that antibiotic use in midlife was significantly associated with subsequent poorer scores for global cognition, learning and working memory, and psychomotor speed and attention on a cognitive assessment administered a mean of 7 years later. This relationship was associated with longer duration of antibiotic use and
persisted after adjustment for many potential confounding factors. We also found consistent associations within strata defined according to medical comorbidities, age, and antidepressant use. To our knowledge, our study represents the first large study of chronic long-term use of antibiotics and subsequent cognition.

Clinical observations have linked extreme neurologic changes such as encephalopathy to short-term antibiotic use. Among hospitalized patients, psychosis may occur within days after fluoroquinolone or macrolide administration [29]. Furthermore, rates of delirium caused by cefepime, a fourth-generation cephalosporin approach 15% [30]. Although such effects have been largely attributed to direct central nervous system neurotoxicity, recent experimental studies suggest a more complex antibiotic-cognition relationship. High-dose, broad-spectrum antibiotic administration in mice (designed to mimic germ-free states) caused cognitive

Table 1. Age-standardized characteristics of NHS2 participants with cognitive assessments (2014–2018), according to midlife antibiotic use reported between 2005 and 2009.

|                           | None (n = 3,398) | < 15 d (n = 5,816) | 15 d–2 mo (n = 4,133) | 2 mo+ (n = 1,195) |
|---------------------------|-----------------|-------------------|----------------------|------------------|
| Mean age at cognitive assessment, y (SD)* | 61.7 (4.6) | 61.7 (4.6) | 61.8 (4.7) | 61.5 (4.6) |
| Spouse’s education level, % |                 |                   |                      |                  |
| High school or less, %      | 14.4            | 15.4              | 15.2                 | 16.5             |
| College degree, %           | 42.5            | 43.0              | 44.0                 | 38.2             |
| Graduate school, %          | 31.2            | 30.2              | 28.3                 | 29.5             |
| Unmarried/unknown, %        | 11.9            | 11.4              | 12.5                 | 15.8             |
| Highest parental education level, % |         |                   |                      |                  |
| High school or less, %      | 45.3            | 48.7              | 48.1                 | 47.3             |
| College degree, %           | 25.4            | 23.9              | 23.9                 | 24.9             |
| Graduate school, %          | 27.0            | 24.1              | 24.8                 | 24.5             |
| BMI, kg/m2 (SD)             | 26.2 (5.7)      | 27.2 (6.1)        | 28.1 (6.5)           | 28.7 (6.9)       |
| Physical activity, MET-h/wk (SD) | 24.7 (22)   | 23.7 (22.2)       | 21.3 (20.6)          | 21 (21.3)        |
| Smoking status, %           |                 |                   |                      |                  |
| Never                      | 68.2            | 66.2              | 64.0                 | 64.3             |
| Former                     | 28.8            | 29.1              | 31.0                 | 29.5             |
| Current                    | 2.9             | 4.6               | 4.8                  | 6.1              |
| Alcohol consumption, %      |                 |                   |                      |                  |
| None, %                    | 14.5            | 12.6              | 12.3                 | 11.4             |
| 1–14 g/day, %              | 63.1            | 64.6              | 62.3                 | 61.6             |
| Type 2 diabetes, %         | 3.3             | 4.3               | 6.6                  | 9.8              |
| Myocardial infarction, %    | 0.6             | 1.2               | 1.0                  | 1.4              |
| Hypertension, %             | 25.5            | 31.6              | 35.3                 | 41.0             |
| High cholesterol, %         | 44.8            | 50.2              | 55.2                 | 59.2             |
| Stroke, %                  | 0.6             | 1.0               | 1.2                  | 1.5              |
| Emphysema, %               | 0.8             | 1.8               | 4.1                  | 7.1              |
| Regular anti-depressant use, %b, c | 14.1          | 19.6              | 25.7                 | 32.3             |
| Regular aspirin use, %b     | 7.6             | 10.3              | 10.3                 | 10.9             |
| Regular NSAID use, %b       | 35.7            | 40.8              | 44.0                 | 44.1             |
| Regular multivitamin use, %b| 52.2            | 54.1              | 56.6                 | 52.7             |
| AHEI 2010d                  | 54.6 (10.2)     | 53.8 (10.2)       | 52.9 (10)            | 52.6 (9.8)       |

*Value is not age-adjusted.

bParticipants who responded ‘yes’ when asked whether they had regularly used aspirin, NSAIDs, antidepressants, or multivitamins over the preceding two years.

Antidepressant use assessed at time of CogState testing.

Alternative Healthy Eating Index, higher scores associated with lower risks of chronic diseases.

https://doi.org/10.1371/journal.pone.0264649.t001
Table 2. Mean differences in cognitive scores according to midlife antibiotic use.

| Composite score | Estimates (95% CI) for mean difference in cognitive scores according to duration of midlife antibiotic use** |
|-----------------|----------------------------------------------------------------------------------------------------------|
|                 | None | < 15 d | 15 d– 2 mo | 2 mo+ | P<sub>trend</sub> |
| **Global cognition** | | | | | |
| Model 1<sup>a</sup> | 0.00 | -0.02 (-0.05, 0.004) | -0.04 (-0.07–0.007) | -0.11 (-0.16,-0.07) | <0.0001 |
| Model 2<sup>b</sup> | 0.00 | -0.01 (-0.04, 0.01) | -0.02 (-0.05, 0.01) | -0.08 (-0.12,-0.03) | 0.002 |
| **Psychomotor speed, attention** | | | | | |
| Model 1<sup>a</sup> | 0.00 | -0.005 (-0.04, 0.03) | -0.02 (-0.06, 0.02) | -0.13 (-0.19,-0.07) | <0.0001 |
| Model 2<sup>b</sup> | 0.00 | 0.002 (-0.04, 0.04) | -0.002 (-0.04, 0.04) | -0.10 (-0.16,-0.04) | 0.004 |
| **Learning, working memory** | | | | | |
| Model 1<sup>a</sup> | 0.00 | -0.04 (-0.07,-0.01) | -0.06 (-0.09,-0.02) | -0.10 (-0.14,-0.05) | <0.0001 |
| Model 2<sup>b</sup> | 0.00 | -0.03 (-0.06,0.00) | -0.03 (-0.07,0.00) | -0.06 (-0.11,-0.01) | 0.03 |

Tests for trend were conducted using the median of the duration of antibiotic therapy as a continuous variable.

<sup>a</sup>Model 1: Adjusted for age and educational attainment of parents and spouse.

<sup>b</sup>Model 2: Adjusted for variables included in Model 1 plus smoking status, body mass index, alcohol intake, physical activity, antidepressant use and symptoms of depression, aspirin use, NSAID use, Alternative Healthy Eating Index score, multivitamin use, and history of hypertension, stroke, type 2 diabetes, myocardial infarction, emphysema, or high cholesterol. All were assessed at the time of exposure except antidepressant use and symptoms of depression, which were asked about at the time of CogState testing.

To assist in interpretation of the CogState score data, the mean difference in score associated with one year of age in these models was (-0.03) for global cognition, (-0.04) for psychomotor speed and attention, and (-0.03) for learning and working memory.

https://doi.org/10.1371/journal.pone.0264649.t002

Table 3. Mean differences in global cognitive scores according to midlife antibiotic use within specific subgroups.

| Composite score | Estimates (95% CI) for mean difference in cognitive scores** |
|-----------------|----------------------------------------------------------------------------------------------------------|
|                 | None | < 15 d | 15 d– 2 mo | 2 mo+ | P<sub>trend</sub> | P<sub>int</sub> |
| **Global cognition** | | | | | | |
| Age ≤ 65 (10,600) (@ time of CogState) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.009 (-0.04, 0.02) | -0.02 (-0.06, 0.01) | -0.07 (-0.12,-0.02) | 0.006 | |
| Age > 65 (4,182) (@ time of CogState) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.03 (-0.08, 0.03) | -0.003 (-0.06, 0.06) | -0.10 (-0.19, -0.008) | 0.17 |
| **Global cognition** | | | | | | |
| No use of antidepressants, 2013 (13,417) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.01 (-0.04, 0.02) | -0.01 (-0.05, 0.02) | -0.09 (-0.14,-0.03) | 0.007 | |
| Use of antidepressants, 2013 (n = 3,116) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.007 (-0.08, 0.06) | -0.02 (-0.09, 0.05) | -0.06 (-0.15, 0.03) | 0.13 | |
| **Global cognition** | | | | | | |
| Hx of MI/CVA/emphysema/DM2 (n = 1,365) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.02 (-0.15, 0.10) | -0.06 (-0.19, 0.06) | -0.12 (-0.27, 0.02) | 0.06 | |
| None of the above (n = 13,417) | | | | | | |
| Model<sup>+</sup> | 0.00 | -0.02 (-0.04, 0.01) | -0.02 (-0.05, 0.02) | -0.08 (-0.13,-0.03) | 0.005 | |

Tests for trend were conducted using the median of the duration of antibiotic therapy as a continuous variable.

<sup>+</sup>Model: Adjusted for age and educational attainment of parents and spouse plus smoking status, body mass index, alcohol intake, physical activity, antidepressant use and symptoms of depression, aspirin use, NSAID use, Alternative Healthy Eating Index score, multivitamin use, and history of hypertension, stroke, type 2 diabetes, myocardial infarction, emphysema, or high cholesterol (with exception of the stratification variable). All were assessed at the time of exposure except antidepressant use and symptoms of depression, which were asked about at the time of CogState testing.

To assist in interpretation of the CogState score data, the estimated difference in score associated with one year of increasing age was -0.03 for overall cognition, -0.04 for psychomotor speed and attention, and -0.03 for learning and working memory.

Abbreviations: Hx, history; MI, myocardial infarction; CVA, cerebrovascular accident; DM2, Type 2 diabetes mellitus.

https://doi.org/10.1371/journal.pone.0264649.t003
deficits, altered gut microbial profiles, and modulated cognition-related signaling molecules like neuropeptide Y, serotonin transporter, and NA subunit [19].

Epidemiologic data for long-term use of antibiotics in relation to cognition are limited and examine much different contexts than our study. Antibiotic exposure in infancy was associated with lower overall cognitive and verbal comprehension abilities at 11 years of age, as well as depressive symptoms at 3 years [21,22]. These two studies suggest a potential latency between antibiotic use and later neurocognitive symptoms, although it is difficult to extend findings from infant antibiotic use to those in our research of adults. For cardiovascular disease, which is associated with cognition, we previously observed an association between antibiotic use at mid-life (age 40–60) and risk of incident cardiovascular disease with aging (beyond age 60) in our cohort of older women, the Nurses’ Health Study [13]. Finally, in a multicenter randomized clinical trial among patients with Alzheimer’s disease, 12 months of treatment with antibiotics led to declines in cognitive scores compared to placebo [23]. Thus, there is some support for relations of antibiotic use to long-term health in aging.

Given the profound effect of antibiotic use on the gut microbiome—with prior studies showing alterations in functional potential at 2 [14] and 4 years [18] after antibiotic exposure—the gut-brain axis could be a possible mechanism for linking antibiotics to cognitive function. Indeed, over the last decade, there has been emerging data linking intestinal bacteria to the brain-gut axis [1–5]. Recent cross-sectional data from small studies indicate large taxonomic differences in gut microbiomes from patients with Alzheimer’s Disease when compared to healthy controls [9,31]. Experimental data demonstrate potential causal mechanisms that might underly these associations. Inoculation of mice with the oral bacterium *Porphyromonas gingivalis* led to greater production of brain amyloid plaques, the hallmark pathology of Alzheimer dementia [6]. In another study, modulation of gut microbes in mice with an antibiotic cocktail led to reductions in accumulation of brain amyloid tangles [7]. Further still, mice colonized by *Lactobacillus* species performed better on retention tests than uncolonized mice [32].

Strengths of our analysis include our large sample, and extensive characterization of participants, enabling control for multiple potential confounding variables, including socioeconomic status, diet, other medications, and medical illnesses. Furthermore, the validity of CogState has been established previously [33].

We acknowledge several limitations. Our antibiotic data do not contain information about route or specific antibiotic type. Additionally, antibiotic information was based on self-report several years after use, and thus may be subject to misclassification and/or recall bias. Further, our data are limited to women. Since cognitive function may differ in women and men, as well as across racial and ethnic groups, further studies in diverse populations are needed. Additionally, due to a lack of power, we cannot directly link microbial features with cognition scores in this cohort. Finally, as in any observational study, we cannot exclude unmeasured and residual confounding. We acknowledge that in this hypothesis-generating study, participants who used antibiotics were more likely to use other medications and/or have comorbid conditions, which could be a proxy for poorer health status, such as chronic infection, which has been linked to cognition [34]. Nevertheless, the associations we observed persisted after adjustment for and stratification by multiple comorbidities.

**Conclusions**

In summary, we found that chronic antibiotic use during midlife was associated with minor decreases in cognitive scores assessed a mean of 7 years later. These data provide a better understanding of potential complications of antibiotics throughout life, as well as generate hypotheses about the role of the gut microbiome in cognition.
Supporting information
S1 Table. Mean differences in cognitive scores according to reason for midlife antibiotic use.

Acknowledgments
We would like to thank the participants and staff of the Nurses’ Health Study II for their valuable contributions.

Author Contributions
Conceptualization: Raaj S. Mehta, Paul Lochhead, Andrew T. Chan.
Data curation: Francine Grodstein, Andrew T. Chan.
Formal analysis: Raaj S. Mehta, Paul Lochhead, Yiqing Wang, Wenjie Ma, Long H. Nguyen, Bharati Kochar, Curtis Huttenhower, Andrew T. Chan.
Funding acquisition: Francine Grodstein, Andrew T. Chan.
Investigation: Raaj S. Mehta, Andrew T. Chan.
Methodology: Raaj S. Mehta, Bharati Kochar, Francine Grodstein.
Project administration: Andrew T. Chan.
Software: Curtis Huttenhower.
Supervision: Francine Grodstein, Andrew T. Chan.
Writing – original draft: Raaj S. Mehta, Andrew T. Chan.
Writing – review & editing: Paul Lochhead, Yiqing Wang, Wenjie Ma, Long H. Nguyen, Bharati Kochar, Curtis Huttenhower, Francine Grodstein, Andrew T. Chan.

References
1. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28:203–9. PMID: 25830558
2. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology 2019; 4:623–32. https://doi.org/10.1038/s41564-018-0337-x PMID: 30718849
3. Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nature Communications 2020; 11:1612. https://doi.org/10.1038/s41467-020-15457-9 PMID: 32235826
4. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013; 155:1451–63. https://doi.org/10.1016/j.cell.2013.11.024 PMID: 24315484
5. Palma GD, Lynch J, Lu J, Dang VT, Deng Y, Jury J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Science Translational Medicine 2017; 9. https://doi.org/10.1126/scitransmed.aaf6397 PMID: 28251905
6. Dominy SS, Lynch C, Ermini F, Benedy M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science Advances 2019; 5:eaau3333. https://doi.org/10.1126/sciadv.aau3333 PMID: 30746447
7. Dodiya HB, Frith M, Sidebottom A, Cao Y, Koval J, Chang E, et al. Synergistic depletion of gut microbial consortia, but not individual antibiotics, reduces amyloidosis in APPPS1-21 Alzheimer’s transgenic mice. Scientific Reports 2020; 10:8183. https://doi.org/10.1038/s41598-020-64797-5 PMID: 32424118
8. Minter MR, Hinterleitner R, Meisel M, Zhang C, Leone V, Zhang X, et al. Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APP
9. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep 2017; 7:13537. https://doi.org/10.1038/s41598-017-13601-y PMID: 28377387

10. Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr 2014; 168:1063–9. https://doi.org/10.1001/jamapediatrics.2014.1539 PMID: 25265089

11. Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, et al. Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cancers (Basel) 2019; 11. https://doi.org/10.3390/cancers11122031 PMID: 31888295

12. Cao Y, Wu K, Mehta R, Drew DA, Song M, Lochhead P, et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut 2018; 67:672–8. https://doi.org/10.1136/gutjnl-2016-313413 PMID: 28377387

13. Heianza Y, Zheng Y, Ma W, Rimm EB, Albert CM, Hu FB, et al. Duration and life-stage of antibiotic use and risk of cardiovascular events in women. Eur Heart J 2019; 40:3838–45. https://doi.org/10.1093/eurheartj/ehz231 PMID: 31216010

14. Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nature Communications 2016; 7:10410. https://doi.org/10.1038/ncomms10410 PMID: 26811868

15. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555:623–8. https://doi.org/10.1038/nature25979 PMID: 29555994

16. Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, et al. Recovery of gut microbiota of healthy adults following antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108 Suppl 1:4554–61. https://doi.org/10.1073/pnas.1000087107 PMID: 20847294

17. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108 Suppl 1:4554–61. https://doi.org/10.1073/pnas.1000087107 PMID: 20847294

18. Doan T, Worden L, Hintenwirth A, Arzika AM, Maliki R, Abdou A, et al. Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution. New England Journal of Medicine 2020; 383:1941–50. https://doi.org/10.1056/NEJMoa2002606 PMID: 33170844

19. Fröhlich EE, Farzi A, Mayerhofer R, Reichmann F, Jaćan A, Wagner B, et al. Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. Brain Behav Immun 2016; 56:140–55. https://doi.org/10.1016/j.bbi.2016.02.020 PMID: 26923630

20. Wang RP-H, Ho Y-S, Leung WK, Goto T, Chang RC-C. Systemic inflammation linking chronic periodontitis to cognitive decline. Brain Behav Immun 2019; 81:63–73. https://doi.org/10.1016/j.bbi.2019.07.002 PMID: 31296811

21. Slykerman RF, Thompson J, Waldie KE, Murphy R, Wall C, Mitchell EA. Antibiotics in the first year of life and subsequent neurocognitive outcomes. Acta Paediatrica 2017; 106:87–94. https://doi.org/10.1111/apa.13613 PMID: 27701771

22. Slykerman RF, Coomarasamy C, Wickens K, Thompson J, Stanley TV, Barthow C, et al. Exposure to antibiotics in the first 24 months of life and neurocognitive outcomes at 11 years of age. Psychopharmacology 2019; 236:1573–82. https://doi.org/10.1007/s00213-019-05216-0 PMID: 31049324

23. Molloy DW, Standish TI, Zhou Q, Guyatt G, DARAD Study Group. A multicentered, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer’s disease: the DARAD trial. Int J Geriatr Psychiatry 2013; 28:463–70. https://doi.org/10.1002/gps.3846 PMID: 22718435

24. Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, et al. Sugar-swetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004; 292:927–34. https://doi.org/10.1001/jama.292.8.927 PMID: 15328324

25. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005; 62:758–65. https://doi.org/10.1001/archneur.62.5.758 PMID: 15883263

26. Sumner JA, Hagan K, Grodstein F, Roberts AL, Harel B, Koenen KC. Posttraumatic stress disorder symptoms and cognitive function in a large cohort of middle-aged women. Depression and Anxiety 2017; 34:356–66. https://doi.org/10.1002/da.22600 PMID: 28072503

27. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology 2017; 153:971–979.e4. https://doi.org/10.1053/j.gastro.2017.06.061 PMID: 28728964
28. Chiuve SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr 2012; 142:1009–18. https://doi.org/10.3945/jn.111.157222 PMID: 22513989

29. Bhattacharyya S, Darby RR, Raibagkar P, Castro LNG, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology 2016; 86:963–71. https://doi.org/10.1212/WNL.0000000000002455 PMID: 26888997

30. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EFM, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care 2013; 17: R264. https://doi.org/10.1186/cc13094 PMID: 24200336

31. Saji N, Niida S, Murotani K, Hisada T, Tsuduki T, Sugimoto T, et al. Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. Scientific Reports 2019; 9:1008. https://doi.org/10.1038/s41598-018-38218-7 PMID: 30700769

32. Mao J-H, Kim Y-M, Zhou Y-X, Hu D, Zhong C, Chang H, et al. Genetic and metabolic links between the murine microbiome and memory. Microbiome 2020; 8:53. https://doi.org/10.1186/s40168-020-00817-w PMID: 32299497

33. Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, et al. Evaluation of the Usability of a Brief Computerized Cognitive Screening Test in Older People for Epidemiological Studies. NED 2010; 34:65–75. https://doi.org/10.1159/000264823 PMID: 20016215

34. Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MSV. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology 2013; 80:1209–15. https://doi.org/10.1212/WNL.0b013e3182896e79 PMID: 23530151